Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study (Q46712990)
Jump to navigation
Jump to search
scientific article published in September 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study |
scientific article published in September 2005 |
Statements
1 reference
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study (English)
1 reference
A N Gordon
1 reference
N Finkler
1 reference
R P Edwards
1 reference
A A Garcia
1 reference
M Crozier
1 reference
D H Irwin
1 reference
E Barrett
1 reference
1 September 2005
1 reference
15
1 reference
5
1 reference
785-792
1 reference